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Abstract 
Background: Recent studies have reported elevated prostaglandin levels in patients with renal artery stenosis and 
hypertension. To investigate whether adistinction between essential hypertension a d hypertension with renal artery 
stenosis is possible by measuring eicosanoid excretion, we studied the excretion of these compounds in patients with 
essential hypertension and in hypertensives with concomitant renal artery stenosis. 
Methods: The 24-h urinary excretion of metabolites of prostaglandin I2, prostaglandin E 2 and metabolites of 
thromboxane A 2 was  sampled under standardised conditions, in 15 patients with essential hypertension and in 15 
patients with unilateral renal artery stenosis with hypertension. Also clinical and biochemical characteristics of the 
subjects were analysed. 
Results: The patients with renal artery stenosis had significantly lower excretion of prostaglandin I 2 than did the 
essential hypertensive patients. However, the overlap in the values was large, thus not allowing a diagnostic 
differentiation according to urinary prostaglandin I z levels. The excretion of prostaglandin E 2 and of metabolites of 
thromboxane A 2 showed no significant differences among the groups. 
Conclusions: Measurement of urinary prostaglandin or prostaglandin metabolite xcretion did not contribute to 
the non-invasive detection of the presence of a renal artery stenosis in the patients in this study. 
Keywords: Hypertension; Renal artery stenosis; Urinary prostaglandin excretion 
1. Introduction 
Prostaglandin endoperoxides are constituents 
of the renal regulatory mechanism of angioten- 
* Corresponding author. Tel. (080) 614782; Fax (080) 
541734. 
sin-induced hypertension, both in the animal 
model and in humans [1-4]. In animal studies it 
was shown that in renin-angiotensin-dependent 
hypertension the levels of plasma 6-ketopros- 
taglandin FI~, a stable metabolite of prostaglandin 
12 (PGI2), and thromboxane B 2 (PGB2) , a stable 
metabolite of thromboxane A 2 (PGA2) , are ele- 
vated and that also urinary excretion of 6-keto- 
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prostaglandin F1, and PGB2 is increased [2]. 
Recent studies in humans have revealed that in 
subjects with renal artery stenosis, systemic 
plasma levels of prostaglandin E 2 (PGE 2) are 
higher than in patients with essential hyperten- 
sion and that the renal vein plasma levels of 
PGE 2 are higher on the stenotic side than on the 
non-stenotic side [3,4]. Also levels of PGI2 and of 
PGA 2 were shown to be elevated in renal artery 
stenosis in humans [5-9]. 
The prostaglandins have a predominantly va- 
sodilator effect at the level of the afferent 
glomerular arteriole [10,11]. The intrarenal ef- 
fects of the renin-angiotensin system are mainly 
confined to the efferent arteriole and exert a 
vasoconstrictor effect through angiotensin II, 
whose effects are partly mediated via the vaso- 
constrictive activity of PGA 2 [1,10]. These micro- 
circulatory changes act to preserve glomerular 
filtration fraction in states of impaired renal per- 
fusion pressure [8,13]. If renal perfusion pressure 
declines, PGI 2 production in the endothelial ceils 
of the vas afferens rises [7]. The PGI 2 in turn 
potentiates renin release by the juxtaglomerular 
apparatus [12,14]. 
Recent experiments have confirmed the im- 
portance of the mechanisms described in renal 
artery stenosis (RAS) in humans [3,4,8,15,16]. In- 
travenous aspirin lowered PGE 2 and renin con- 
centrations, in the human renal vein from the 
kidney distal to an unilateral RAS, with concomi- 
tant lowering of the blood pressure [3]. A signifi- 
cant decline in PGE 2 and renin concentrations, 
after the administration of aspirin, was also re- 
ported in the renal veins distal to a unilateral 
RAS, in patients in whom blood pressure was 
cured or improved after percutaneous translumi- 
nal renal angioplasty, but not in patients in whom 
blood pressure did not improve after the relief of 
a renal artery stenosis [4]. Thus, by inhibiting 
PGE 2 production, renin production was attenu- 
ated and blood pressure fell, at least in the acute 
experiments [3,4]. 
On the basis of these experiments it can be 
assumed that in renovascular hypertension the 
renal production of PGE 2, PGI 2 and PGA 2 is 
increased [2-4]. In essential hypertension the 
eicosanoids do not seem to participate directly in 
the control of arterial pressure and their levels 
have not been shown to be raised [8,17]. Thus, by 
measuring renal prostaglandin production itmight 
be possible to differentiate between essential hy- 
pertension and hypertension with a unilateral 
RAS. 
The least invasive and most reliable way of 
assessing intrarenal prostaglandin production is 
to measure the urinary excretion of PGE 2, 6-ke- 
toprostaglandin Fla , and PGB 2 [18]. Only a slight 
day-to-day variation in the excretion of PGE 2 has 
been reported [19]. We measured the 24-h uri- 
nary excretion of these eicosanoids in patients 
with essential hypertension and in patients with 
unilateral renal artery stenosis and hypertension, 
to examine whether the assumed ifferences in 
urinary prostaglandin excretion would be appar- 
ent. 
2. Patients and methods 
Included in the study were 15 patients with 
essential hypertension and 15 patients with hy- 
pertension and a unilateral renal artery stenosis. 
Hypertension was defined as a supine blood pres- 
sure, taken on 3 different occasions, above 90 
mmHg diastolic on each occasion. The diagnosis 
of essential hypertension was made if laboratory 
investigation and angiography had excluded sec- 
ondary forms of hypertension. Subjects with pro- 
teinuria over 1.5 g a day, haematuria or abnor- 
malities on urine microscopy were excluded. Sub- 
jects with diabetes mellitus were also excluded 
from the study. The diagnosis of unilateral renal 
artery stenosis was made if on a Seldinger arteri- 
ography or on an arterial digital subtraction an- 
giography a luminal narrowing of more than 70% 
of the surface was present. Fifteen successive 
patients were selected in whom a diagnosis of 
renal artery stenosis was made. The patients were 
included if their characteristics were in agree- 
ment with the protocol as outlined above. The 
subjects with essential hypertension were also 15 
successive patients in whom the diagnosis of es- 
sential hypertension was made and whose clinical 
data matched the study terms. In all subjects 
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antihypertensive medication .and a sodium-re- 
stricted diet were discontinued at least 2 weeks 
before the urine sampling. In the setting of the 
outpatient department i is hardly possible to 
bring subjects into a fixed sodium balance. We 
assumed that by taking an unlimited sodium diet 
the patients would reach a steady state with re- 
gard to their salt status. All other medication was 
also withheld. Special emphasis was given to pre- 
vent the use of cyclo-oxygenase-inhibiting dru s. 
The patients were asked to refrain from smoking 
and sexual activity from 24 h before the start of 
the urine sampling. 
Urine was sampled uring two successive peri- 
ods of 24 h because, in case of any collection 
problem, there would be a second sample. As 
standard the first of the two samples was used. In 
2 cases the ratio of PGE 2 and prostaglandin F2,~, 
which for this purpose was also measured, was 
over 0.5, indicating that the sample was contami- 
nated by seminal fluid and therefore the second 
sample was used [19]. The creatinine content of 
the urine sample that was used for the study was 
measured to calculate the endogenous creatinine 
clearance (ECC). Twenty-four hour urinary 
sodium content was measured in the same 24-h 
urine as the prostaglandins or, if this was not 
feasible, it was measured in a 24-h urine sample 
of the same week in which the 24-h urine for the 
prostaglandin measurements was taken. 
The levels of PGE 2, PGF2~, 6-keto-PGFa, and 
TxB2 were determined by radioimmunoassays, 
according to procedures described previously 
[20,21]. After 10 consecutive assays the PGE2 
determinations showed 6.4 and 15%, the PGF2, 
assay 5.3 and 11%, the 6-keto-PGFl~ assay 7.3 
and 9.6%, and the TxB 2 assay 8.1 and 12.5% 
intra- and interassay variability, respectively. 
To relate prostaglandin excretion to functional 
renal mass, 24-h urinary prostaglandin metabolite 
excretion was indexed to the 24-h creatinine con- 
tent of the same sample. Plasma renin activity 
(PRA) was measured under baseline conditions, 
meaning that all antihypertensive medications 
were stopped for at least 2 weeks. After blood for 
baseline PRA was taken, patients took an oral 
dose of 25 mg of captopril and 60 min after that 
blood for captopril-stimulated PRA was drawn. 
During this procedure the patients remained in 
the supine position. 
The features of gender, age, body mass index 
(body weight in kilograms divided by the square 
of the length in metres), endogenous creatinine 
clearance, PRA, 24-h urinary sodium content, 
smoking habits and blood pressure levels were 
compared as were the 24-h urinary PGE2, 6-keto- 
PGFI~ and thromboxane B 2 excretion and the 
prostaglandin levels indexed to 24-h creatinine. 
Statistical analysis 
Patient characteristics among the groups were 
compared with Wilcoxon's rank sum test apart 
from the gender and the numbers of smokers, 
who were compared with Fisher's exact est. The 
24-h urinary prostaglandin and prostaglandin 
metabolite excretion were also compared by 
Wilcoxon's rank sum test. Outcomes with a p- 
value of less than 5% were regarded as signifi- 
cant. All tests were performed two-sided. In a 
forward stepwise logistic regression procedure the 
independent relation of age, ECC, body mass 
index, smoking, systolic and diastolic blood pres- 
sure and the diagnosis of essential hypertension 
and renal artery stenosis to the prostaglandin a d 
Table 1 
Clinical characteristics of patients with essential hypertension 
(EH) (n = 15) and patients with renal artery stenosis (RAS) 
(n = 15) 
EH RAS 
Gender (F /M)  5/10 3/12 
Age (yrs) 45 (20-63) 53 (21-74) 
Body mass index (kg/m 2) 25 (21-33) 25 (21-31) 
Urinary Na (mmol/24 h) 155 (40-313) 154 (40-200) 
ECC (ml/min) 94 (64-141) 82 (29-124) 
No. of smokers (%) 1 (6%) * * 9 (60%) 
Systolic blood pressure 170 (140-240) 184 (144-220) 
(mmHg) 
Diastolic blood pressure 108 (80-150) 110 (80-130) 
(mmHg) 
Median and (between brackets) the range are indicated, un- 
less indicated otherwise. ECC = endogenous creatinine clear- 
ance. ** Indicates significant difference between EH and 
RAS, p < 0.01. 
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Table 2 
Urinary prostaglandin metabolite xcretion and plasma 
hypertension a d renal artery stenosis RAS (n = 15) 
renin activity in essential hypertensives (EH) (n = 15) and patients with 
EH RAS 
6-Ketoprostaglandin FI~(nmol/24 h) 
Prostaglandin E 2 (nmol/24 h) 
Thromboxane B 2 (nmol/24 h) 
1.9 (0.54-3.6)*  1.1 (0.28-2.5) 
0.87 (0.09-13) 0.8 (0.23-5.3) 
1.2 (0.3-2.1) 1.2 (0.42-2.7) 
Prostaglandin metabolite xcretion (nmol / I ~ 24 h) indexed to urinary creatinine xcretion (mmol / I / 24 h) 
6-Ketoprostaglandin F1, ~ 0.13 (0.07-0.28) * 0.08 (0.04-0.27) 
Prostaglandin E 2 0.05 (0.01-1.02) 0.06 (0.02-0.45) 
Thromboxane B e 0.08 (0.04-0.21) 0.12 (0.03-0.36) 
Plasma renin actiuity (nmol / l / h) 
Baseline 
After 25 mg of captopril 
0.87 (0.1-3.96) 1.9 (0.4-7.7) 
1.24 (0.1-2.89)*  9.8 (0.1-51.1) 
Given are Medians and between brackets ranges. * * Indicates difference p < 0.01; * indicates difference p < 0.05. 
prostaglandin metabolite excretion were anal- 
ysed. 
3. Results 
The study included 15 patients with essential 
hypertension and 15 with unilateral RAS. All 
patients with RAS had atherosclerotic vascular 
narrowing as evidenced by angiography. 
The number of smokers was significantly higher 
in the patients with RAS (Table 1). The clinical 
features of gender, age and body mass index were 
not significantly different among the groups (Ta- 
ble 1). Twenty-four hour urinary sodium excre- 
tion was also not significantly different: median 
155 (range 40-313) mmol/24 h in the EH group 
and 154 (40-200) mmol/24 h in the group with 
RAS (Table 1). Blood pressure in the essential 
hypertensives and in those with RAS was not 
significantly different: 170 (140-240)/108 (80- 
150) and 184 (144-220)/110 (80-130) mmHg, 
respectively (Table 1). Baseline PRA was 0.87 
(0.1-3.96) nmol/1/h in the EH group and 1.9 
(0.4-7.7) nmol/ l /h  in the RAS group, which was 
not significantly different (Table 2). The capto- 
pril-stimulated PRA was significantly higher in 
the patients with RAS: 9.8 (0.1-51.1) vs. 1.24 
(0.1-2.89) nmol/ I /h in the EH group (Table 2). 
In the group of essential hypertensives there was 
no significant rise in PRA after captopril, but in 
the patients with a RAS the rise in PRA after 
captopril was significant (Table 2). Twenty-four 
hours 6-keto-prostaglandin F1, ~ excretion was with 
a median of 1.1 (0.28-2.5) nmol/24 h signifi- 
cantly lower in the patients with RAS as com- 
pared with the value of 1.9 (0.54-3.6) nmol/24 h 
in the essential hypertensives (Table 2). Also in- 
dexed to the 24-h creatinine xcretion, 24-h 6-ke- 
toprostaglandin FI~ excretion was significantly 
lower in the patients with RAS; 0.08 (0.04-0.28) 
vs. 0.13 (0.07-0.27) nmol/mmol (Table 2). Re- 
garding the other prostaglandins and prostaglan- 
din metabolites, no significant differences in the 
values for the 24-h urinary excretion among the 
groups were detected. 
In the forward stepwise logistic procedure the 
diagnosis of renal artery stenosis l~owed a signifi- 
cant relationship to the 24-h 6-ketoprostaglandin 
F1, urinary excretion (r e = 0.30, p < 0.01). Fur- 
thermore, PGB 2 excretion showed a significant 
relation to smoking (r 2 = 0.22, p < 0.01). 
4. Discussion 
Because renovascular hypertension can be 
treated successfully in a large number of patients, 
it is worthwhile to try to identify those with this 
condition among the general hypertensive popu- 
lation [22-25]. However, the certain diagnosis of 
a renal artery stenosis can only be made by an- 
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giography [22-25]. In view of the low prevalence 
of renal artery stenosis in the hypertensive popu- 
lation, angiography, because of its invasive nature 
and cost, cannot be used as a screening proce- 
dure. Therefore a sensitive and reliable non-inva- 
sive screening procedure that can detect his con- 
dition would be an important ool in clinical 
practice. 
A number of studies have shown that in the 
case of stimulation of the renin-angiotensin ys- 
tem, especially as a result of renal ischaemia, 
renal eicosanoid production rises [1-9]. Since a 
significant renal artery stenosis is a situation of 
renal ischaemia, it might be expected that this 
condition results in an elevated renal prostaglan- 
din production. Thus, by assessing renal 
eicosanoid production, which can be done reli- 
ably and non-invasively by measuring urinary 
prostaglandin and prostaglandin metabolite x- 
cretion, the presence of a renal artery stenosis 
should be detectable if the concomitant hyperten- 
sion is related to the stenosis and therefore 
renin-angiotensin-mediated. 
The patients with a RAS in the present study 
showed a significant rise in PRA after the admin- 
istration of captopril, indicating the renin depen- 
dency of their renal haemodynamic regulation, as 
compared with the absence of such a rise in the 
essential hypertensive patients. 
However, the expected higher levels of urinary 
prostaglandin excretion were not present in the 
group with RAS. On the contrary, we found a 
significantly lower 6-keto-prostaglandin FI~ ex- 
cretion in the patients with a unilateral RAS. 
How can these results be explained? One dif- 
ference between the groups is the number of 
smokers, which was higher in the patients with 
RAS. To exclude as much as possible the acute 
effects of smoking, the participants were asked to 
refrain from smoking for at least 24 h. Most of 
the clinical studies concerning eicosanoid produc- 
tion do not mention smoking habits of the stud- 
ied population and in one study smoking discon- 
tinuation of 3 h was considered long enough to 
minimize its effects on eicosanoid levels [26]. Cre- 
ating a group of non-smoking patients with RAS 
would have introduced considerable bias, as 
atherosclerotic renal artery disease is strongly 
linked to smoking. Smoking causes a rise in 
platelet-derived prostaglandin production, mainly 
of TxA 2 and, probably vessel-wall-derived, 
prostaglandin 12 as measured by the elevated 
urinary excretion of their metabolites TxB 2 and 
6-ketoprostaglandin FI~ [27,28]. We could not 
substantiate such a rise because the levels of 
TxB 2 were  comparable in the two groups, al- 
though TxB 2 excretion showed a relation to 
smoking. The level of PGI 2 was lower in the 
group of RAS with the highest number of smok- 
ers. Because smoking would have enhanced the 
differences expected, it seems very unlikely that 
the difference in smoking could have substantially 
influenced the results of prostaglandin 12and of 
6-ketoprostaglandin Fad excretion. Apart from 
TxB2, the other prostanoid excretions also did 
not show a relation to smoking. 
Other causes of diminished 6-ketoprostaglan- 
din F~ excretion might be found in a difference 
in functional renal mass or the presence of 
parenchymal renal disease. A severely diminished 
renal mass can cause a decline in renal 
prostaglandin production because renal tissue 
produces the renal prostanoids. Renal parenchy- 
mal diseases can give rise to various changes in 
renal prostaglandin production including an in- 
crease or decrease of the excretion depending on 
the offending condition [29-32]. However, be- 
tween the two groups the endogenous creatinine 
clearance was not statistically different, indicating 
a comparable renal functional mass, and also the 
eicosanoid excretion indexed to creatinine xcre- 
tion showed a lower 6-ketoprostaglandin FI~ ex- 
cretion in the patients with a RAS, which makes 
a diminished functional renal mass unlikely as the 
cause of the different findings. As we excluded 
patients with parenchymal renal disease, the dif- 
ference in eicosanoid excretion can also not be 
explained by possible renal diseases. 
What other explanation for the results of the 
present study might be valid? In a recent study of 
renal vein prostaglandin concentrations before 
and after cyclo-oxygenase inhibition with aspirin 
DL-lysine it was found that the level of 
prostaglandins in the veins of the stenotic kidney 
was increased in relation to the other kidney and 
declined within 30 mins after intravenous aspirin 
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DL-lysine [3,4]. Although the level of the 
prostaglandins in the aorta was also higher than 
in patients with essential hypertension and low 
renin, they were not lower than in essential hy- 
pertensive patients with high renin, and as renal 
flow was not measured it remains unclear if renal 
prostaglandin production was in fact increased. If
the concentration changes were caused by changes 
in flow, it is clear that such changes cannot be 
detected by differences in 24-hour urinary 
eicosanoid excretion. 
As there were no significant differences in 
baseline PRA between our patients with essential 
hypertension and those with RAS, it might well 
be that the only differences present in such pa- 
tients are differences in prostaglandin concentra- 
tions between the affected and non-affected renal 
veins. 
To elucidate this problem, both hormone con- 
centrations and renal blood flow have to be stud- 
ied. Probably then an explanation can be given 
for the absence of the expected ifferences in 
prostaglandin excretion in the present study. 
Due to the overlap in individual values, 6-keto- 
prostaglandin FI~ excretion could also not be 
used to make a diagnostic differentiation between 
the subjects. Thus, by measuring the concentra- 
tions of renal prostaglandin or prostaglandin 
metabolites in the urine, no distinction could be 
made between essential hypertension and hyper- 
tension with renal artery stenosis. 
References 
[1] Wilcox CS, Welch WJ. Angiotensin II and thromboxane 
in the regulation of blood pressure and renal function. 
Kidney Int 1990; 38(suppl 30):$81-83. 
[2] Lin L, Mistry M, Stier CT Jr, Nasjletti A. Role of 
prostanoids in renin-dependent and renin independent 
hypertension. Hypertension 1991; 17:517-525. 
[3] Imanishi M, Kawamura M, Akabane S, et al. Aspirin 
lowers blood pressure in patients with renovascular hy- 
pertension. Hypertension 1989; 14:461-468. 
[4] Imanishi M, Kawamura M, Akabane S, et al. The utility 
of aspirin for differential diagnosis of renovascular hyper- 
tension from hyperreninemic essential hypertension. AJH 
1991; 4:761-768. 
[5] Blackshear JL, Spielman WS, Knox FG, Romero JC. 
Dissociation of renin release and renal vasodilation by 
prostaglandin synthesis inhibitors. Am J Physiol 1979; 
237:F20-F24. 
[6] Jackson EK, Gerkens JF, Brash AR, Branch RA. Acute 
renal artery constriction increases renal prostaglandin I 2
biosynthesis and renin release in the dog. J Pharmacol 
Exp Ther 1982; 222:410-413. 
[7] Romero JC, Knox FG. Mechanisms underlying pressure- 
related natriuresis: the role of the renin-angiotensin a d 
prostaglandin systems. Hypertension 1988; 11:724-738. 
[8] Romero JC, Strong CG. The effect of indomethacin 
blockade of prostaglandin synthesis on blood pressure of 
normal rabbits and rabbits with renovascular hyperten- 
sion. Circ Res 1977; 40:35-41. 
[9] McGiff JC. Interactions of prostaglandins with the 
kallikrein-kinin and renin-angiotensin systems. Clin Sci 
1980; 59:105s-l16s. 
[10] Edwards RM. Segmental effects of norepinephrine and 
angiotensin II on isolated renal microvessels. Am J Phys- 
iol 1983; 244:F526. 
[11] Edwards RM. Effects of prostaglandins on vasoconstric- 
tor action in isolated renal arterioles. Am J Physiol 1985; 
248:F779. 
[12] Olivari MT, Levine TB, Cohn JN. Evidence for a direct 
renal stimulating effect of prostaglandin E 2 on renin 
release in patients with congestive heart failure. Circula- 
tion 1986; 74:1203-1207. 
[13] Packer M. Interaction of prostaglandins and angiotensin 
II in the modulation of renal function in congestive heart 
failure. Circulation 1988; 77(suppl I):I-64. 
[14] Beierwaltes WH, Schrijver S, Sanders E, Strand J, 
Romero JC. Renin release selectively stimulated by 
prostaglandin 12 in the isolated rat glomeruli. Am J 
Physiol 1982; 243:F276-F283. 
[15] Levenson DJ, Dzau VJ. The effects of angiotensin con- 
verting enzyme inhibition in renal artery stenosis. Kidney 
Int 1987; 31:173-179. 
[16] Johnston CI, Jackson B. Overview: angiotensin convert- 
ing enzyme inhibition in renovascular hypertension. Kid- 
ney Int 1987; 31:154-156. 
[17] Terragno NA, Terragno DA, McGiff JC. Contribution of 
prostaglandins tothe renal circulation in conscious, anes- 
thesized, and laparotomized ogs. Circ Res 1977; 
40:590-595. 
[18] Frohlich JC, Wilson TW, Sweetman BJ et al. Urinary 
prostaglandins: identification and origin. J Clin Invest 
1975; 55:763-772. 
[19] Koopmans PP, Thomas ChMG, van de Berg RJ, Thien 
Th. The urinary excretion of prostaglandins and throm- 
boxane B 2 in healthy volunteers: a study in males and 
females, and on the influence of seminal fluid contamina- 
tion. Prostaglandins Leukotrienes Essential Fatty Acids 
1988; 32:107-111. 
[20] Thomas CMG, van de Berg RJ, de Koning-Gans HJ, 
Lequin RM. Radio-immunoassays for prostaglandins: 
technical validation of prostaglandin F2, ~ measurements 
in human plasma using Sephadex G-25 gel filtration. 
Prostaglandins 1978; 15:839-847. 
C.T. Postma et aL /Netherlands Journal of Medicine 47 (1995) 99-105 105 
[21] Thomas CMG, van de Berg RJ, de Koning-Gans HJ, 
Lequin RM. Radio-immunoassays for prostaglandins: 
measurement of prostaglandin E 2 and the 13,14-dihydro- 
15-keto metabolites of the E and F series. Description of 
a reliable technique with an universal applicability. 
Prostaglandins 1978; 15:849-855. 
[22] Postma CT, van der Steen PHM, Hoefnagels WHL, de 
Boo Th, Thien Th. The captopril test in the detection of 
renovascular disease in hypertensive patients. Arch In- 
tern Med 1990; 150:625-628. 
[23] Svetkey LP, Himmelstein SI, Dunnick NR, et al. 
Prospective analysis of strategies for diagnosing renovas- 
cular hypertension. Hypertension 1989; 14:247-257. 
[24] Postma CT, van Oijen A, Barentsz JO, de Boo Th, 
Hoefnagels WHL, Thien Th. The value of tests predict- 
ing renovascular hypertension i  patients with renal artery 
stenosis treated by angioplasty. Arch Intern Med 1991; 
151:1531-1535. 
[25] Mann S J, Pickering TG, Sos TA, et al. Captopril renog- 
raphy in the diagnosis of renal artery stenosis: accuracy 
and limitations. Am J Med 1991; 90:30-40. 
[26] Fitzgerald GA, Smith B, Pedersen AK, Brash AR. In- 
creased prostacyclin biosynthesis n patients with severe 
atherosclerosis and platelet activation. N Engl J Med 
1984; 3410:1065-1068. 
[27] Nowak J, Murray J J, Oates JA, FitzGerald GA. Bio- 
chemical evidence of a chronic abnormality in platelet 
and vascular function in healthy individuals who smoke 
cigarettes. Circulation 1987; 76:6-14. 
[28] Chiabrando C, Rivoltella L, Alberti E, Bonollo M, Dju- 
rup R, Fanelli R. Urinary excretion and origin of ll-de- 
hydro-2,3-dinor-thromboxane B 2 in man. Prostaglandins 
1993; 45:401-411. 
[29] Oates JA, FitzGerald GA, Branch RA, Jackson EK, 
Knapp HR, Jackson Roberts L. Clinical implications of 
prostaglandin and thromboxane formation. Part I. N Engl 
J Med 1988; 319:689-698. 
[30] Pierucci A, Simonetti BM, Pecci G, et al. Improvement 
of renal function with selective thromboxane antagonism 
in lupus nephritis. N Engl J Med 1989; 320:421-425. 
[31] Eriksson L-A, Sturfelt G, Thysell H, Wollheim FA. Ef- 
fects of sulindac and naproxen on prostglandin excretion 
in patients with impaired renal function and rheumatoid 
arthritis. Am J Med 1990; 89:313-321. 
[32] Mizuiri S, Takano M, Hayashi I, Aikawa A, Ohara T, 
Hasegawa A. Effect of prostaglandins on renal function 
in uninephrectomized humans. Nephron 1993; 63:429- 
433. 
